Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 24, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 225,000 Ordinary shares of 25 pence each.
- Purchase Date: October 24, 2011.
- Price Range: Highest price paid was 1,398 pence per share; lowest price paid was 1,386 pence per share.
- Treasury Holdings (Settled): 508,161,370 shares (9.12% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,714,248 shares (10.05% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,062,840,796 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 225,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.05% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,062,840,796) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.05% including unsettled shares).
- Review the price paid per share (1,386 to 1,398 pence) against market prices on October 24, 2011.
- Note that this filing does not contain operational or financial performance data for the period.